Amgen's Tavneos Faces Proposed U.S. Withdrawal Over Liver Injury Deaths on May 22; Unapproved in China

GateNews

According to Amgen's statement on May 22, the U.S. FDA has proposed withdrawing approval for Tavneos (avelumab), a rare disease treatment, following reports of liver injury-related deaths. The drug was previously approved in China as well.

Amgen China confirmed that Tavneos received approval from the National Medical Products Administration (NMPA) in November 2024 but has not been commercialized in China. As of May 22, no patients in China have received treatment with the drug.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments